Congenital anomalies of the kidneys and urinary tract (CAKUT) are the most common cause of chronic kidney disease in children. As CAKUT is a genetically heterogeneous disorder and most cases are genetically unexplained, we aimed to identify new CAKUT causing genes. Using whole-exome sequencing and trio-based de novo analysis, we identified a novel heterozygous de novo frameshift variant in the leukemia inhibitory factor receptor (LIFR) gene causing instability of the mRNA in a patient presenting with bilateral CAKUT and requiring kidney transplantation at one year of age. LIFR encodes a transmembrane receptor utilized by IL-6 family cytokines, mainly by the leukemia inhibitory factor (LIF). Mutational analysis of 121 further patients with severe CAKUT yielded two rare heterozygous LIFR missense variants predicted to be pathogenic in three unrelated patients. LIFR mutants showed decreased half-life and cell membrane localization resulting in reduced LIF-stimulated STAT3 phosphorylation. LIFR showed high expression in human fetal kidney and the human ureter, and was also expressed in the developing murine urogenital system. Lifr knockout mice displayed urinary tract malformations including hydronephrosis, hydroureter, ureter ectopia, and, consistently, reduced ureteral lumen and muscular hypertrophy, similar to the phenotypes observed in patients carrying LIFR variants. Additionally, a form of cryptorchidism was detected in all Lifr -/-mice and the patient carrying the LIFR frameshift mutation. Altogether, we demonstrate heterozygous novel or rare LIFR mutations in 3.3% of CAKUT patients, and provide evidence that Lifr deficiency and deactivating LIFR mutations cause highly similar anomalies of the urogenital tract in mice and humans. †
Introduction
Congenital anomalies of the kidneys and urinary tract (CAKUT) comprise various structural malformations that result from defects in the morphogenesis of the kidneys or the urinary tract including kidney agenesis (absence of kidney), renal dysplasia (kidney with abnormal structures), renal hypoplasia (reduced kidney size and number of nephrons), hydronephrosis (distention of the renal pelvis), hydroureter (increased ureter size), and vesicoureteral reflux (VUR, retrograde movement of urine from the bladder to the ureter or kidney) (1) . Although each of these phenotypes is rare, all malformations together are quite frequent (observed in three to six per 1,000 live births (2)). As chronic kidney disease (CKD) requiring dialysis or kidney transplantation in severe cases is caused by CAKUT in around 50% of children (3) , these anomalies represent a significant health burden. Although familial occurrence with dominant as well as recessive inheritance has been described, most CAKUT cases are sporadic, i.e. there is a single symptomatic case per family (4) . While over 500 syndromes are associated with CAKUT, most cases are isolated, i.e. no other organs are involved (5) . To date, around 36 genes are known to cause isolated CAKUT or CAKUT with mild extra-renal manifestations when mutated, whereby less than 20% of CAKUT cases are caused by mutations in these genes (6) , indicating the high genetic heterogeneity of this disorder. Therefore, in the last few years, next generation sequencing (NGS) technologies providing exome-wide sequence information have been used to identify novel CAKUT causing genes and to give new insights into the pathogenesis of these malformations (7) (8) (9) (10) (11) (12) .
Because a dominant disorder can result from a de novo mutation, and most CAKUT cases are sporadic, we analyzed a trio consisting of a patient and his unaffected parents by wholeexome sequencing (WES) and performed trio-based de novo analysis. In the patient, we identified a de novo frameshift variant in the leukemia inhibitory factor receptor (LIFR) gene, which was heterozygous and novel. LIFR encodes a transmembrane receptor composed of 1097 amino acid residues containing three main domains, i.e. an extracellular region responsible for ligand binding, a non-polar transmembrane domain, and a cytoplasmic region exerting downstream effects (13) . LIFR can form multimeric complexes with other receptors such as glycoprotein 130 (gp130) that are utilized by several interleukin-6 (IL-6) cytokine family members including the leukemia inhibitory factor (LIF) to stimulate JAK/STAT, MAPK, and PI3K signaling (14) . Lifrdeficient mice die perinatally due to pleiotropic defects including severe osteopenia, high stores of liver glycogen, and a reduced number of astrocytes and neurons in the spinal cord and brain stem impairing the respiratory rhythm and suckling, whereas the urogenital system has not been examined to date (15, 16) . Homozygous or compound heterozygous null mutations in LIFR have been described causative of Stü ve-Wiedemann syndrome (STWS [MIM: 601559]) (17), a very rare disorder characterized by congenital bowing of the long bones, respiratory distress, feeding difficulties, and hyperthermic episodes (18) (19) (20) (21) (22) (23) (24) (25) (26) . While the frequency of renal manifestations in STWS is unknown because the severe autonomic nervous system and osteodysplastic symptoms cause lethality in the neonatal period or infancy in most cases, hypoplastic and hydronephrotic kidneys have been described in one STWS patient (27) .
Here, we provide evidence for a causative role of deactivating LIFR mutations and Lifr deficiency in the pathogenesis of urinary tract and kidney anomalies via LIFR mutational screening of a CAKUT patient cohort as well as in vitro and in vivo characterization of this gene or identified variants thereof in cellular and mouse models.
Results
A novel heterozygous de novo LIFR frameshift variant was detected in whole blood DNA of patient A004 using WES Under the assumption that disorders such as CAKUT, which may be dominantly inherited, can be caused by de novo mutations, trio-based de novo analysis was performed using exome data from whole blood derived DNA of the unaffected parents and their affected son (patient A004). Using this strategy and defined quality scores (coverage ! 20, call quality ! 50, allele fraction ! 40%), 54 coding de novo variants were identified in the patient (Supplementary Material, Table S1 ). Considering only variants that were non-silent (i.e. essential splice site, frameshift, in-frame indels, stop gained/lost, or non-synonymous missense variants), rare (i.e. with a minor allele frequency (MAF) < 1%), and not present in a control cohort of 65 individuals not affected by CAKUT, five de novo variants remained in the patient, two of which were predicted to be deleterious by the prediction tools SIFT, PROVEAN, PolyPhen-2, or MutationTaster, and one of which was shown to be truly de novo by Sanger sequencing (Supplementary Material, Table  S1 ). This variant, LIFR,c.1273_1276delGTTA;p.Val425Ilefs*2 (chr5:38506022_ 38506025del, exon 8, GRCh37/hg19), was found to be heterozygous in the patient and not inherited from his parents ( Fig. 1A and B, Table 1 ). The variant is a novel LIFR frameshift mutation predicted to truncate the encoded protein in the second cytokine receptor homology domain, resulting in a substantially shortened protein lacking parts of the extracellular domain as well as the transmembrane and the cytoplasmic domains (Fig. 1C) . To explore whether inherited variants, which are not detectable by trio-based de novo strategy, could also play a causative role in the CAKUT phenotype of patient A004, we extracted variants in known CAKUT genes from his WES data, and screened for homozygous and compound heterozygous variants in his entire WES data set. No rare nonsilent variants predicted to be deleterious and not present in controls were identified in the 36 known CAKUT genes (6) . Considering the whole exome, no rare homozygous or compound heterozygous non-silent variants predicted to be deleterious and not present in controls were detected.
Fibroblasts of patient A004 carry the LIFR variant, show strongly reduced mutant mRNA and significantly decreased full-length LIFR protein abundance
We amplified LIFR exon 8 on genomic DNA from fibroblasts of patient A004, performed Sanger sequencing, and ascertained that the LIFR variant c.1273_1276delGTTA;p.Val425Ilefs*2 was also present heterozygously in this cell type ( Fig. 1D and Supplementary Material, Fig. S1 ). Amplification of LIFR exon 8 on fibroblast complementary DNA (cDNA) and direct sequencing revealed that the mutant transcript was strongly underrepresented ( Fig. 1D and Supplementary Material, Fig. S1 ), and a truncated LIFR protein could not be detected in fibroblast lysates by Western blot analysis using an N-terminal antibody (data not shown), indicating nonsense-mediated decay of most mRNA containing the c.1273_1276delGTTA variant in ex vivo cultures. We then analyzed whether full-length LIFR protein levels were reduced in fibroblasts of patient A004 compared to fibroblasts of three age and sex matched controls not carrying a LIFR Figure 1 . Whole-exome and targeted sequencing identifies heterozygous novel or rare LIFR mutations in four of 122 CAKUT patients (3.3%). (A) WES followed by triobased de novo analysis detected the LIFR,c.1273_1276delGTTA,p.Val425Ilefs*2 variant in patient A004, verified to be heterozygous and not inherited from the healthy parents by Sanger sequencing (the first affected nucleotide is marked by an arrow, region of deletion is marked by a line). (B) Pedigree of family A004 with clinically healthy parents and affected child. (C) Exon structure of human LIFR and encoded domains (protein domains are according to (25, 29, 31) and Uniprot (http://www.uni variant as determined by Sanger sequencing of all exons and adjacent splice sites of LIFR (data not shown). Detection of fulllength LIFR protein in fibroblast lysates by Western blot analysis using a C-terminal antibody and data quantification revealed significantly reduced levels in patient A004 versus controls ( Fig.  1E and F ). In addition, by flow cytometry analysis using a phycoerythrin(PE)-conjugated antibody raised against the extracellular region of LIFR we found that the expression of LIFR protein at the cell surface of non-permeabilized living cells was significantly reduced in fibroblasts of patient A004 compared to fibroblasts of the three controls ( Fig. 1G and H) .
Three of 121 further CAKUT patients carry rare heterozygous LIFR missense variants predicted to be deleterious
To investigate the frequency of LIFR variants in CAKUT patients, we screened a cohort of 121 further CAKUT cases for variants in LIFR either by WES (23 patients) or targeted sequencing (98 patients) of the entire coding region including canonical splice sites of the LIFR gene. In three patients, two different heterozygous non-synonymous missense variants in the LIFR gene were identified that were rare (MAF < 1%) and predicted to be deleterious (Table 1, Fig. 1C ). The variant detected in patient N002, LIFR,c.1937C > A;p.Thr646Asn (chr5:38493836, exon 13, GRCh37/ hg19), is a known missense variant (rs79040751) that is rare (MAF: 0.002315) and predicted to be damaging by SIFT. It was inherited from the patient's mother (Fig. 1I) . The amino acid threonine at position 646 is located within the extracellular domain of LIFR and its exchange is described as a nonconservative substitution (Grantham difference [range: 0 to 215]: 65). The variant found in the two patients N023 and B007, LIFR,c.3288C > A;p.Asn1096Lys (chr5:38481703, rs3729751, exon 19, GRCh37/hg19), was a rare (MAF: 0.001761) missense variant predicted to be disease causing by MutationTaster, damaging by SIFT and probably damaging by PolyPhen-2. The variant carried by patient B007 was paternally inherited, while parental DNA of patient N023 was not available (Fig. 1I) . The amino acid asparagine at position 1096, which is located in the cytoplasmic domain of LIFR, is highly conserved (conservation score GERP [range: -12.3 to 6.17]: 5.94), and the amino acid exchange is described as a non-conservative substitution (Grantham difference: 94). In two of the three families, in which inheritance of the LIFR missense variants from clinically healthy parents was shown, the parents may in fact have a subtle CAKUT phenotype only detectable by renal ultrasound that was not performed, or variants in additional genes may have contributed to CAKUT pathogenesis in the patients. In 65 in-house control exomes, no rare non-silent variants predicted to be deleterious were detected in the LIFR gene.
LIFR mutants show decreased half-life and cell membrane localization resulting in reduced STAT3 phosphorylation
As the LIFR transcript encoded by the c.1273_1276delGTTA variant is subjected to nonsense-mediated decay ( Fig. 1D and Supplementary Material, Fig. S1 ), we suspected that the LIFR variants identified in CAKUT patients are deactivating. Therefore, we analyzed whether protein turnover of ectopically expressed LIFR variants was increased. Hep3B cells that do not express endogenous LIFR (28) Fig.  2A) . Next, we compared the abundance of plasma membranelocalized receptor after in vitro expression of wildtype and mutant LIFR in non-permeabilized living HEK293T cells using a PEconjugated antibody raised against the extracellular region of LIFR and evaluation by flow cytometry. After expressing the respective constructs in vitro, variant p.Val425Ilefs*2 predicted to lack the transmembrane and cytoplasmic domains was shown to migrate at a molecular weight of approx. 60 kDa compared to approx. 190 kDa of wildtype LIFR (Supplementary Material, Fig.  S2B ), and was not detectable at the plasma membrane by flow cytometry (Fig. 2B) . Membranous LIFR was also diminished after transfection with constructs expressing c.1937C > A;p.Thr646Asn and c.3288C > A;p.Asn1096Lys variants compared to wildtype LIFR (Fig. 2B) . All variants showed a significantly decreased cell membrane signal compared to wildtype LIFR after normalization to total expressed LIFR protein ( Fig. 2C and Supplementary Material, Fig. S2B ). Reduced cell membrane localization of LIFR mutants versus wildtype protein was confirmed by confocal imaging of immunofluorescently labeled receptor in fixed HEK293T cells (Fig. 2D) .
To determine a potential functional consequence of LIFR mutants on downstream signaling pathways, we analyzed STAT3 prot.org); Box1, box1 motif; CRH, cytokine receptor homology domain; FNIII, type III fibronectin domain; Ig, Ig-like domain; SP, signal peptide; WSXWS, WSXWS motif). Fig. S1 ). (E,F) Detection (E) and quantification (F) of full-length LIFR protein by Western blot analysis using a C-terminal antibody revealed a significant reduction of relative protein levels in fibroblast lysates of patient A004 compared to fibroblast lysates of three age and sex matched controls not carrying a LIFR mutation. Values represent the mean 6 SD (error bars) of four independent experiments. *P < 0.05. (G,H) By flow cytometry (G), fibroblasts of patient A004 showed significantly reduced levels of LIFR protein at the surface of intact cells compared to fibroblasts of three age and sex matched controls not carrying LIFR mutations; MFI, median fluorescence intensity (H). Values represent the mean 6 SD (error bars) of three independent experiments. *P < 0.05. (I) Pedigrees and electropherograms demonstrating the rare variant LIFR,c.1937C > A;p.Thr646Asn, which is heterozygous in patient N002 and his mother, and the rare variant LIFR,c.3288C > A;p.Asn1096Lys, which is heterozygous in patient N023 (parental DNA was not available) as well as in patient B007 and his father. By in silico analysis, all variants were predicted to be deleterious. Parents were clinically unaffected but not examined by renal ultrasound, so that a mild, e.g. unilateral, CAKUT phenotype cannot be excluded. LIFR is expressed in fetal and adult human kidney and in the developing murine urogenital system
To further investigate a possible role for LIFR in CAKUT pathogenesis, we determined LIFR expression in the human and murine kidney and ureter during development and in adulthood. Quantification of LIFR mRNA levels using cDNA panels from various fetal and adult human tissues and real-time PCR showed highest fetal LIFR expression in the brain followed by the kidney (Fig. 3A) . LIFR was also expressed in the adult human kidney, although its mRNA levels were much lower than in the fetal kidney. By immunohistochemistry on human normal kidney sections, LIFR localizes to proximal tubules and thin medullary tubules probably corresponding to loops of Henle, but predominantly to the urothelium of the renal pelvis and ureter, particularly to the superficial layer (Fig. 3B ).
To determine whether Lifr is expressed in the developing murine urogenital system, we performed RNA in situ hybridization on whole-mount preparations and sections of urogenital systems from NMRI wildtype mice at embryonic day (E)11.5 to E18.5 ( Fig. 3C and D) . Lifr expression was widespread with highest levels in the kidney at E16.5 on whole-mount preparations (Fig. 3C) . Analysis of Lifr expression on sections of E12.5 kidneys revealed low expression confined to the mesenchymal compartment including the cap mesenchyme. This domain was also found in E18.5 kidney sections. Additionally, mRNA signals were detected in thin tubules probably representing loops of Henle, and strong Lifr expression was found in the nerves around the urethra at E18.5. In the ureter, Lifr expression was strongest in the innermost layer of the urothelium at this stage (Fig. 3D) .
Lifr knockout mice show urinary tract malformations including, consistently, a reduced ureteric lumen
To determine whether Lifr deficiency causes a CAKUT phenotype in mice, we compared Lifr and Supplementary Material, Fig. S5A, panel 1 ). In the Lifr -/-embryo, hematoxylin and eosin stained sagittal sections revealed severe hydronephrosis, a dilated renal collecting system, and a blind-ending ureter (Fig. 4A, panel 1) . By evaluation of hematoxylin and eosin stained sagittal sections from the other urogenital systems, the following milder anomalies were detected in Lifr -/-embryos: minor hydronephrosis, hydroureter, and microcystically dilated tubules (1/10), minor hydronephrosis and ureter ectopia (1/10), ureter ectopia and microcystically dilated tubules (1/10) (Fig. 4A, panel 2) , microcystically dilated tubules (2/10), and renal dysplasia (1/10). In total, seven of 10 (70%) Lifr -/-embryos showed severe (1/10) or milder (6/10)
anomalies, while three of 10 (30%) Lifr -/-embryos had unaffected urinary tracts or kidneys (Fig. 4A, panel 3 To investigate the differentiation of the ureteric mesenchymal wall, in situ hybridization was performed utilizing marker gene expression on the smooth muscle (SM) layer, the lamina propria, and the tunica adventitia ( Fig. 4B and Supplementary Material, Fig. S6B ). Genes encoding SM structural proteins (Tnnt2 and Myh11) and the key regulator of SM cell differentiation (Myocd) showed a slight downregulation on the proximal and medial ureter levels in Lifr -/-embryos. However, expression of all SM markers, predominantly Myh11 expression, was upregulated in the distal part of the ureter in Lifr -/-embryos, indicating hypertrophy of the distal ureter wall. The thickness of the ureteric SM layer as well as the urothelium were also significantly increased in Lifr -/-compared to Lifr þ/þ embryos when evaluating hematoxylin and eosin stained sections ( Fig. 4D and E) . Urothelium thickness was also enhanced in Lifr þ/-versus Lifr To further characterize the kidney phenotype in Lifr -/-mice, we analyzed the kidneys of 14 Lifr þ/þ and 14 Lifr -/-E15.5 embryos for macroscopic and microscopic morphometric changes (Fig. 5) .
The kidney size of Lifr -/-embryos was significantly reduced compared to that of Lifr þ/þ embryos (Fig. 5A) . Immunohistochemical analysis revealed a significant reduction of comma shaped bodies, premature glomeruli, and all glomerular developmental stages per kidney section in Lifr -/-compared to Lifr þ/þ embryos ( Fig. 5B-F) . Similar findings were obtained by 3D evaluation of renal glomerulogenesis showing a significant reduction of glomerular number per kidney volume and of glomerular volume in Lifr -/-versus Lifr þ/þ embryos (Fig. 5I-L) . Significantly fewer cells showed STAT3 and ERK1/2 phosphorylation in cross-sections of Lifr -/-versus Lifr þ/þ embryo kidneys by immunohistochemistry ( Fig. 5G and H) . Thus, a significant reduction of kidney size and nephron number was found in Lifr -/-E15.5 embryos indicating renal hypoplasia.
Reverse phenotyping reveals distal ureter muscular hypertrophy in patient A004
A nephrectomy specimen was available from patient A004 carrying the de novo LIFR frameshift mutation c.1273_1276delGT TA;p.Val425Ilefs*2, which was obtained at time of kidney transplantation at one year of age. Kidney and transverse distal ureter sections were hematoxylin and eosin stained and re-evaluated by a Nephropathologist for this study. Similar to the findings in Lifr -/-mouse embryos, severe muscular wall hypertrophy and fibrosis were diagnosed in the distal ureter ( Fig. S7 ). Clinically, patient A004 had required ureterocutaneostomy at the age of six weeks because of severe distal ureteric obstruction.
Discussion
In this study, we demonstrate that mutations in LIFR, encoding a transmembrane receptor utilized by the IL6 cytokine family, can cause malformations of the urogenital tract and the kidneys in humans, and that Lifr deficiency causes highly similar anomalies in mice. While genetic studies of familial CAKUT have identified important novel CAKUT associated genes (e.g. 7,8,10), we chose a sporadic patient as the starting point of our study because most CAKUT patients are sporadic cases. Therefore, the genetic analysis of sporadic CAKUT patients is epidemiologically highly relevant and needs to be pursued by those who aim to identify the genetic cause in the majority of patients. A possible strategy in disorders in which dominant inheritance has been described is to assume de novo occurrence of causative mutations warranting trio-based de novo analysis of WES data. As DNA was available from both healthy parents, we aimed at identifying the genetic CAKUT basis in patient A004, who carried no deleterious variants in known CAKUT genes, using this approach. The heterozygous de novo LIFR frameshift variant detected in patient A004 is predicted to result in a substantially shortened protein lacking the transmembrane domain, the cytoplasmic region containing the box1 motif required for association with JAK kinases (29) as well as the membrane-proximal extracellular region, i.e. three fibronectin type III domains and the WSXWS motif, involved in receptor dimerization and activation (30, 31) . However, in fibroblasts of patient A004 a truncated protein was not detectable, consistent with the finding that cDNA analysis indicated nonsense-mediated decay of mRNA containing the LIFR frameshift variant. Similarly, most LIFR mutations resulting in STWS are null mutations that cause mRNA instability preventing the formation of truncated LIFR protein (25) . In CAKUT patient A004 carrying the LIFR frameshift variant in a heterozygous state, full-length protein as well as functional receptor at the cell surface were significantly diminished in fibroblasts suggesting haploinsufficiency as a malformation mechanism.
LIFR is an attractive CAKUT candidate gene. Firstly, combined hydronephrosis and renal hypoplasia have been described in a patient with STWS (27), a syndrome caused by biallelic LIFR mutations (17) . Since this disorder usually results in infant mortality (25) precluding detailed analysis of all involved organ systems, the prevalence of CAKUT in STWS may be underestimated. Secondly, gp130, the dimerization partner of the transmembrane receptor encoded by LIFR, and the cytokine LIF, the main ligand acting on LIFR-gp130 heterodimers, have been implicated in the development of the kidneys and urinary tract. LIF has been attributed a role in the first step of metanephric induction, the ureter outgrowth, and in regulating mesenchymal to epithelial conversion and tubule formation in the metanephric mesenchyme (32, 33) . While abnormalities of the kidneys or urinary tract were not described for Lif-deficient mice (34), suggesting redundancy with related cytokines or a minor phenotype that has not been detected so far, kidneys from gp130-deficient mouse embryos showed reduced nephrogenesis at E15 (32) . Thirdly, but more indirectly, a number of other transmembrane receptors have been implicated in the development or in anomalies of the kidneys and urinary tract such as fibroblast growth factor receptor (FGFR) 1, 2, and 11 (35) , angiotensin II receptor, type 1 (AGTR1) (36), roundabout, axon guidance receptor, homolog 2 (ROBO2) (37), proto-oncogene tyrosine-protein kinase receptor (RET) (38) , and integrin alpha 8 (ITGA8) (8) . Therefore, we screened a cohort of patients with severe CAKUT for LIFR variants demonstrating heterozygous novel or rare LIFR variants in 4/122 (3.3%) CAKUT patients. Considering that only around 17% of CAKUT cases are explained by mutations in the 36 genes causing isolated CAKUT or syndromic CAKUT with mild extra-renal manifestations described previously (6) , this is quite a high percentage.
In line with our in vivo evidence, in vitro analyses indicate that the LIFR variants identified in our CAKUT patients act as hypomorphs. In vitro evidence for LIFR haploinsufficiency as a CAKUT causing mechanism comes from the findings that LIFR mutants show decreased half-life and cell membrane localization resulting in reduced LIF-stimulated phosphorylation of STAT3, a major signal downstream of cytokine receptors. Similarly, mutant integrin alpha 8 was not detected at the cell surface in cells ectopically expressing an ITGA8 missense variant detected in a CAKUT family (8) , suggesting an impaired transport of the variant receptor to the cell membrane as a pathomechanism in CAKUT patients carrying ITGA8 or LIFR mutations. Comparable to the hypomorphic effect of the identified LIFR mutations when expressed in vitro, we detected that STAT3 phosphorylation was diminished in kidney sections from Lifr -/-versus Lifr þ/þ embryos. Our results are in line with previous studies reporting that STAT3 phosphorylation is essential for epithelial tubulogenesis (39) , and that LIF receptor activation of STAT3 may play a central role during renal development (32) . A role for LIFR in urogenital system development is further supported by our findings that LIFR expression is high in human fetal kidneys, and that Lifr is expressed in the developing murine urogenital system. While the Lifr expression is rather ubiquitous in whole-mount preparations at E11.5 to E16.5, this does not preclude a role in urogenital tract development. At a later stage, the Lifr expression pattern was more specific with strongest expression in the cap mesenchyme, the loop of Henle, and the urothelium, which was similar to LIFR expression in the human urogenital system. Lifr expression in the cap mesenchyme, i.e. the precursor pool for nephrons, is consistent with a role for LIF, the main LIFR ligand, in mesenchymal to epithelial conversion and tubule induction in the metanephric mesenchyme as shown previously (32, 33) .
Although pleiotropic defects have been described in Lifr-deficient mice, including disruption of the placental architecture, profound mineralized bone loss, increased liver glycogen levels, and a reduction in numbers of astrocytes and motor neurons in the spinal cord and brainstem, the urogenital system of these mice has not been examined (15, 16 Because Lifr -/-embryos appeared smaller as described previously (15, 16) , they may suffer from generalized developmental delay, and the reduced kidney size may be seen in this context. Alternatively, smaller size of Lifr -/-embryos could be caused by the osteodysplasia described in Lifr -/-mice and STWS patients (15, 16, 25, 26) rather than by developmental retardation. Similar to the renal hypoplasia found here in Lifr -/-embryos at E15.5, gp130-depleted mouse embryos at E15 displayed smaller kidneys with significantly less glomeruli and S-shaped bodies than controls (32) . Taken together, the findings in Lifr -/-mouse embryos were highly similar to phenotypes found in our patients carrying LIFR mutations including ureteral obstruction, hydronephrosis, and renal hypodysplasia. More similarities between LIFR mutation carriers and Lifr -/-mouse embryos were found in other organs. A consistent genital phenotype detected in the male Lifr -/-mouse embryos was a ligamentous tethering of the testis to the dorsal aorta, possibly corresponding to remnants of the cranial suspensory ligament. While the regression of this ligament in males permits testis descent, persistence has been linked to retention of the testis in the abdominopelvic cavity (40) , and may thus cause cryptorchidism in Lifr -/-embryos. Comparably, a form of cryptorchidism ('sliding testis') was detected in CAKUT patient A004 carrying the LIFR frameshift mutation suggesting an effect of LIFR mutations and Lifr deficiency on genital development in mice and humans. Similarly, the combination of renal dysplasia and megaureters with cryptorchidism has been described in a patient carrying mutations in RET (41), another gene known to cause CAKUT when mutated (38) . A close relationship between cryptorchidism and CAKUT is underscored by the finding that abnormal caudal development, including malformation or dysplasia of the kidneys, ureters or lower spine was found in one third of cryptorchid fetuses (42) (43) (44) . Another organ affected in both Lifr-deficient mice and patients carrying LIFR mutations is the brain. While in Lifr-deficient mice reduced numbers of astrocytes and neurons have previously been reported in the spinal cord and brain (15, 16) , we here describe an attention deficit disorder in two of the four patients with LIFR mutations further emphasizing the similarity between mice and humans carrying LIFR aberrations.
In summary, we demonstrate heterozygous novel or rare LIFR mutations in 3.3% of CAKUT patients and provide compelling evidence that Lifr deficiency and deactivating LIFR mutations cause highly similar anomalies of the urogenital tract and kidneys in mice and humans.
Materials and Methods

Patients
The study was approved by the Ethics Boards of Hannover Medical School, Hannover, Germany and Oslo University Hospital, Oslo, Norway; each family provided informed consent for participation in the study. WES was performed on one patient-parent-trio, 23 additional CAKUT patients, and 65 controls, i.e. individuals unaffected by CAKUT and unrelated to the patients; targeted sequencing of the LIFR gene was done on 98 further CAKUT patients. The 122 CAKUT patients analyzed in total comprised 76 males and 46 females with a mean age of 11.5 years (range 1-34 years) and the following phenotypes: bilateral renal dysplasia (n ¼ 39; with obstructive megaureter (n ¼ 3/39) or hydronephrosis (n ¼ 2/39)), unilateral renal dysplasia (n ¼ 5), bilateral cystic renal dysplasia (n ¼ 20), unilateral cystic renal dysplasia (n ¼ 2), bilateral multicystic renal dysplasia (n ¼ 3), unilateral multicystic renal dysplasia (n ¼ 3; with unilateral duplex kidney (n ¼ 1/3)), bilateral duplex kidney (n ¼ 2), unilateral duplex kidney (n ¼ 2; with pelviureteric junction obstruction (PUJO) and obstructive megaureter (n ¼ 1/2)), unilateral dysplastic duplex kidney and unilateral dysplastic triple kidney (n ¼ 1), bilateral renal hypoplasia (n ¼ 1), unilateral renal hypoplasia (n ¼ 2; with bilateral obstructive megaureter (n ¼ 1/2)), unilateral renal agenesis (n ¼ 8; with unilateral renal dysplasia (n ¼ 6/8)), hydronephrosis (n ¼ 3; with obstructive megaureter (n ¼ 1/3)), unilateral PUJO (n ¼ 2), horseshoe kidneys (n ¼ 4; with megaureter (n ¼ 1/4)), or solitary renal cysts (n ¼ 2). Posterior urethral valves (PUV) were diagnosed in 23 patients, 11 of whom had additional renal phenotypes: hydronephrosis (n ¼ 3/23), renal dysplasia (n ¼ 5/23), cystic renal dysplasia (n ¼ 1/23), renal hypoplasia (n ¼ 1/23), unilateral renal agenesis and unilateral renal dysplasia (n ¼ 1/23). Thirty-eight of the CAKUT patients additionally presented with VUR. All patients suffered from CKD, and 33 patients had undergone kidney transplantation. Twenty-seven patients presented with additional extra-renal symptoms: intellectual disability and failure to thrive (n ¼ 5/27), VACTERL association (n ¼ 9/27), ear malformation and hearing loss (n ¼ 3/27), iris coloboma and cataract (n ¼ 4/27), skeletal malformation (n ¼ 4/27), heart defect (n ¼ 2/27), diabetes mellitus (n ¼ 2/27), or epilepsy (n ¼ 1/27).
Case reports of the four patients found to carry heterozygous novel or rare LIFR mutations A novel de novo LIFR frameshift variant was detected in patient A004, while three CAKUT patients (N002, N023, and B007) carried rare heterozygous LIFR missense variants predicted to be deleterious (Table 1, Fig. 1 ).
Patient A004
The male patient is the second child of non-consanguineous German parents and was born full-term. Family history was negative regarding kidney disease. Ultrasound screening during pregnancy revealed right-sided renal agenesis and left-sided hydronephrosis with megaureter. Diagnostic work-up after birth showed a dysplastic kidney with reduced parenchymal thickness, a massive hydronephrosis, and an obstructive megaureter on the left side (Fig. 1J) . Renal agenesis on the right side was confirmed. Voiding cystourethrogram showed no VUR. Because of the ureteral stenosis, left-sided ureterocutaneostomy was performed at six weeks of age. Despite continuous low-pressure urine drainage, kidney function did not improve in the following months, and serum creatinine levels persisted around 250-300 mmol/l. Therefore, at the age of one year, preemptive kidney transplantation from a deceased donor and leftsided nephrectomy were performed because of end-stage renal disease. The patient was also diagnosed with prefascial ectopia of the testis ('sliding testis') and suspected attention deficit disorder.
Patient N002
The patient is the first son of Algerian parents with an unremarkable family history. He was prenatally diagnosed with left hydronephrosis. At two weeks of age, he was hospitalized for failure to thrive and kidney failure. The evaluation showed VUR grade IV bilaterally and a trabecular bladder. PUV were suspected but could not be diagnosed. At the age of nine years, new investigations detected PUV, and resection of the valves was performed. The patient has had a gradual deterioration of kidney function and was pre-emptively transplanted at the age of 14 years from a deceased donor. As the function of the trabecular bladder is not optimal, the patient requires regular intermittent catheterization. The boy has no other abnormalities.
Patient N023
The male patient is a child of non-consanguineous Norwegian parents. He was prenatally diagnosed with left-sided renal agenesis and right-sided hydronephrosis (Fig. 1J) . Family history was unremarkable. Postnatal evaluation confirmed renal agenesis on the left side and revealed a slight PUJO on the right side, which later resolved. The single right kidney showed compensatory hypertrophy. Creatinine was 20 mmol/l and blood pressure was normal at age 2 years. The patient has no other abnormalities.
Patient B007
The male patient is the third child of non-consanguineous German parents born full-term after an unremarkable pregnancy. Family history was negative regarding kidney disease. At the age of six years, he was diagnosed with impaired growth and admitted to hospital for further diagnostics. Because the estimated glomerular filtration rate (eGFR) was 46 ml/min/ 1.73m 2 , renal ultrasound was performed revealing bilateral hypodysplastic kidneys without hydronephrosis. Therefore, growth failure due to CKD was diagnosed. By voiding cystourethrogram, VUR was excluded. At the age of 16 years, eGFR was 33 ml/min/1.73 m 2 . Renal ultrasound showed small, hyperechogenic kidneys with nearly complete loss of corticomedullary differentiation (Fig. 1J) confirming the diagnosis of CKD due to renal hypodysplasia. The patient additionally presents with attention deficit disorder.
Experimental animals and urogenital system isolation
Animals were kept in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals. All experiments were approved by the Ethics Board of the Lower Saxony State Office for Consumer Protection and Food Safety. Lifr þ/-mice that were described previously (15) were purchased from The Jackson Laboratory (B6;129S7-Lifr tm1Imx /J; https://www.
jax.org), and maintained on a Ztm:NMRI outbred background.
To obtain Lifr -/-mice, Lifr þ/-females and males were mated. As Lifr -/-mice die perinatally (15) , embryos were analyzed at E18.5
and E15.5. For timed pregnancies, vaginal plugs were checked in the morning after mating, and noon was considered E0.5. Lifr
littermates served as controls. For analysis of Lifr expression in the developing murine urogenital tract, NMRI wildtype mice were used at different embryonic stages. On E11.5 to E18.5, pregnant females were sacrificed by cervical dislocation. Embryos were derived by Cesarean section, isolated in ice-cold phosphate buffered saline (PBS), and sacrificed by decapitation. Urogenital systems isolated from embryos or entire embryos were fixed. Fixation was performed using 4% paraformaldehyde (PFA) in PBS-buffer followed by subsequent dehydration in methanol. Tissues were stored in 100% methanol at À20 Using conventional chain termination protocols on a 3130XL Genetic Analyzer (Applied Biosystems, Darmstadt, Germany) (i) selected variants remaining after the filtering process of WES data were verified, (ii) and the entire coding region including 19 coding exons and all adjacent splice sites of the LIFR gene were screened for variants on whole blood DNA from 98 CAKUT patients and on fibroblast derived DNA from controls. Exon 8 of the LIFR gene was additionally sequenced on DNA and cDNA from fibroblasts of patient A004. DNA samples from parents of patients found to carry LIFR mutations were obtained for segregation analysis, if possible, and analyzed for the specific variant found in their child. Nucleotide numbering of the variants reflects cDNA numbering in the GenBank (http://www. ncbi.nlm.nih.gov/genbank/) reference sequence NM_002310.5 (LIFR). The three novel or rare non-silent LIFR variants predicted to be deleterious identified here in four CAKUT patients were submitted to ClinVar (SCV accession nos SCV000346032-SCV000346034; http://www.ncbi.nlm.nih.gov/clinvar/).
LIFR expression constructs
The pUNO1 mammalian expression construct harboring the full-length human LIFR cDNA sequence was purchased from InvivoGen (San Diego, CA, U.S.A.). The LIFR expression construct was used as a template to insert (i) the c.1273_1276delGTTA variant identified in patient A004 using the primer pair 5'-ATA TAA CTG AAA AAG TTT ATC CCC ATA CTC CTA CTT CAT TCA AAG-3' and 5'-TAA AAT TGT TGA TTG TGA TCG ACC CAG C-3', (ii) the c.1937C > A variant identified in patient N002 using the primer pair 5'-GAT TCT CCT CAA CTG GCA TTA CGA CC-3' and 5'-CCC TTT CCC ATC CCA ACA ACT TG-3', and (iii) the c.3288C > A variant identified in patients B007 and N023 using the primer pair 5'-CCT TTA CAA ACT TTT TTC AGA ACA AAC CAA AAG ATT AA-3' and 5'-ACC ACC CTC CTC CAT TAG ATT TAG GAG AGT C-3'. Mutagenesis was performed following the standard procedure of the Phusion Site-Directed Mutagenesis Kit (Thermo Fisher Scientific) and generated constructs were verified by direct sequencing.
Cell culture and transient transfection
Hep3B cells were purchased from ATCC (Hep3B2.1-7; Manassas, VA, U.S.A.), cultured in MEM (Merck Millipore, Billerica, MA, U.S.A.) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 1% penicillin/streptomycin solution (all purchased from Thermo Fisher Scientific). For human fibroblasts and HEK293T cells, high-glucose DMEM (Merck Millipore) was used instead of MEM. Cells were transiently transfected using Lipofectamine 3000 Transfection Reagent (Thermo Fisher Scientific) according to standard protocols.
Western blot analysis
Human fibroblasts or transiently transfected Hep3B or HEK293T cells were lysed in Laemmli buffer (62.5 mM Tris/HCl (pH 6.8), 10% glycerol, 2% SDS, 5% 2-mercaptoethanol, 1 mM EDTA, 0.0025% bromophenol blue (w/v)), and lysates were used in equal amounts for SDS-polyacrylamide gel electrophoresis. The following primary antibodies were used for immunodetection: anti-LIFR antibody raised against the N-terminal part of human LIFR (AF-249; R&D Systems, Wiesbaden-Nordenstadt, Germany) and anti-LIFR antibody raised against the C-terminal part of human LIFR (#22779-1-AP 
Flow cytometry
To quantify LIFR expression at the plasma membrane, human fibroblasts or transiently transfected HEK293T cells were harvested from culture plates, and cell number was determined using a Neubauer chamber. Cell suspensions were incubated with PE-conjugated mouse anti-LIFR (FAB249P, R&D Systems) or PE-conjugated mouse anti-IgG1 isotype control (IC002P, R&D Systems), both at 10 mL/10 6 cells, for 30 min at room temperature (RT) in 0.5% BSA/PBS. The samples were transferred to tubes, and fluorescence intensities were measured using a FACSCanto II (Becton Dickinson, Franklin Lakes, NJ, U.S.A.) and analyzed using Flowing Software 2 (Perttu Terho, Turku Centre for Biotechnology, University of Turku, Turku, Finland, http://www. uskonaskel.fi/flowingsoftware/).
Immunofluorescence microscopy
To visualize LIFR expression at the plasma membrane, transiently transfected HEK293T cells were fixed using methanol for 20 min at À20 C. As primary antibody, goat anti-LIFR (AF-249; R&D Systems) was used at 1:200 dilution overnight at 4 C, and as secondary antibody, donkey anti-goat IgG (H þ L) Alexa Fluor 488 (Thermo Fisher Scientific) was used at 1:500 dilution for 1 h at RT. Microscopic imaging was done using a Leica TCS SP2 confocal system (Leica Microsystems, Wetzlar, Germany).
Determining LIF-stimulated variant-specific LIFR activity
To determine which cellular system and conditions to use for assaying variant-specific LIFR activity, LIF concentration and stimulation time were assayed in Hep3B and HEK293T cells. Cells were transiently transfected with empty vector or LIFR expression construct and were stimulated with recombinant human LIF (Sigma-Aldrich) 24 h post-transfection (including serum starvation overnight). Several concentrations of LIF were applied for 10 min and stimulation with 10 ng/ml LIF was performed for 5, 10, 30, 60, and 120 min. Based on the results, transiently transfected Hep3B cells were stimulated with 10 ng/ml recombinant human LIF for 5 min 48 h post-transfection (including serum starvation overnight). Cells were lysed, and STAT3, phosphorylated STAT3 (Tyr705), and GAPDH levels were analyzed by immunoblotting with specific antibodies as described above.
Quantitative messenger RNA expression analysis in human tissues
To quantify LIFR expression in human tissues, relative quantifications in real-time PCR experiments were performed using the TaqMan Gene Expression Assay for LIFR (Hs01123581_m1; Thermo Fisher Scientific) on Human Multiple Tissue cDNA MTC Panel I (#636747, LOT1212243A) and Human Fetal MTC Panel (#636742, LOT1202889A; Clontech-Takara Bio Europe, Saint Germain-en-Laye, France). Each sample was normalized to TaqMan control target beta-2-microglobulin (Hs00187842_m1; Thermo Fisher Scientific), and comparative C t quantification was applied.
Immunohistochemistry on human normal kidney sections
Immunohistochemistry was performed on 3-5 mm sections of formalin-fixed paraffin-embedded non-neoplastic tissue obtained from a nephrectomy specimen surgically resected because of urothelial carcinoma. Sections were mounted on Superfrost slides. The following primary antibodies and dilutions were used: LIFR polyclonal antibody (1:250, #22779-1-AP, Proteintech), THP rabbit polyclonal antibody (1:250, #sc-20631, Santa Cruz Biotechnology), and AQP1 rabbit polyclonal antibody (1:4000, #AB2219, Merck Millipore). Subsequently, slides were treated with a horseradish-peroxidase-labeled goat anti-rabbit secondary antibody (1:200, #A24537, Thermo Fisher Scientific).
Counterstaining was carried out with Mayer's Hemalaun solution. As a negative control, a rabbit IgG isotype control antibody (#3900S, Cell Signaling Technology) was applied. All slides were scanned using the Aperio AT2 Scanner (Leica Microsystems), and digital images were processed using ImageScope v11.2.0.780 software (Leica Microsystems, http://www.leicabio systems.com/digital-pathology/digital-pathology-management/ imagescope/).
RNA in situ hybridization analysis of murine urogenital systems
To detect the spatial-temporal expression of Lifr in the murine urogenital system during embryonic development, nonradioactive whole mount RNA in situ hybridization analysis of embryonic organ rudiments and isolated urogenital systems of NMRI wildtype embryos at E11.5 to E16.5 was carried out following a standard protocol (46) . Stained organ rudiments or whole urogenital systems were transferred into 80% glycerol before they were photographed on a Leica M420 microscope (Leica Microsystems) with a Fujix HC-300Z digital camera (Fujifilm, Tokyo, Japan). To determine the transcriptional profile of Lifr expression in NMRI wildtype embryos in more detail, and to analyze nephron segmentation as well as the status of ureter differentiation in Lifr -/-versus Lifr þ/þ embryos, urogenital systems of NMRI wildtype embryos as well as of Lifr þ/þ and Lifr -/-embryos at different embryonic stages were transferred into paraffin, sectioned, and analyzed by non-radioactive in situ hybridization using digoxigenin-labeled antisense riboprobes on 10 mm sections as previously described (47) . Sections were documented on a Leica DM5000B microscope with a Leica DFC300 FX digital camera (Leica Microsystems). At least three specimens were used per genotype, stage, and molecular marker.
Morphological, histological and immunohistochemical analyses of mouse embryos
For morphological analyses, urogenital systems manually dissected from Lifr
, and Lifr -/-E18.5 mouse embryos were photographed using a Leica S6D microscope with a Leica EC3 camera (Leica Microsystems). At least ten specimens of Lifr
and Lifr -/-mice, and 40 specimens of Lifr þ/-mice were analyzed.
For microscopic evaluation, urogenital systems from E18.5 embryos were fixed in 4% PFA in PBS, paraffin-embedded, and sagittal or transverse sections of 5 mm were cut. Sections were stained with hematoxylin and eosin according to standard protocols, scanned using the Aperio AT2 Scanner (Leica Microsystems), and ureter lumen, wall, and urothelium were measured using ImageScope v11.2.0.780 software (Leica Microsystems). Sagittal sections from at least ten embryos and transverse sections from at least six embryos were analyzed per genotype. For immunohistochemistry, Lifr þ/þ and Lifr -/-E15.5 embryos were fixed in 4% PFA in PBS, dehydrated, and embedded in paraffin. Embedded embryos were cut into serial sections of 2 mm, and each 10th section was stained with PAS to determine the sections with the maximum longitudinal renal area by computer-assisted morphometric analysis using cellSenssoftware (Olympus Deutschland, Hamburg, Germany). For comparative examination of Lifr þ/þ and Lifr -/-embryos, ten sections each with the highest longitudinal renal area were selected for immunohistochemical staining. For all stainings, heat mediated antigen retrieval using antigen retrieval solution (DAKO Deutschland, Hamburg, Germany) was performed. After blocking with normal goat serum and 1% Blocker BLOTTO Blocking Buffer (Thermo Fisher Scientific), sections were incubated overnight at 4 C using the following antibodies diluted in 1% BSA in 50 mM Tris pH 7.4: rabbit anti-Wilms tumor 1 (Wt-1) antibody (Santa Cruz Biotechnology), rabbit anti-phospho-STAT3 (Tyr705) antibody (Cell Signaling Technology), and rabbit anti-phospho-ERK1/2 antibody (Cell Signaling Technology). The number of glomerular developmental stages was determined per renal cross section by counting Wt-1 positive podocytes; pSTAT3 and pERK1/2 positive cells were counted per renal cross section using corresponding antibodies. Binding of biotinylated secondary antibody (goat anti-rabbit, Vector Laboratories, Burlingame, CA, U.S.A.) to primary antibodies was detected using ABC-kit and DABImmpact (both from Vector Laboratories). Negative controls for immunostaining included either omission or substitution of the primary antibody with equivalent concentrations of an irrelevant murine monoclonal antibody or preimmune rabbit IgG. At least 14 specimens were analyzed per genotype. For 3D evaluation of renal glomerulogenesis, urogenital systems of E15.5 embryos were fixed in 4% PFA in PBS, cleared, and immunolabeled using the iDISCO protocol (48) . For staining of the glomeruli, a biotinylated goat anti-podocalyxin antibody (R&D Systems) and a streptavidin Alexa Fluor 555 antibody (Invitrogen, Carlsbad, CA, U.S.A.) were used. Z-stacks of embryonic kidneys were built using a Zeiss laser-scanning microscope LSM710 (Zeiss, Jena, Germany). 3D views from scanned kidneys were built using ZEN-software (Zeiss). For analysis of glomerular number and volume, a 3D object counter plugin and FIJIsoftware were used.
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